Approval · Notice of Compliance 23463 · 2020
ABILIFY: Notice of Compliance 23463
Issued April 15, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23463
- Date
- April 15, 2020
- Company
- Otsuka Pharmaceutical Co LtdChiyoda-Ku Tokyo, --, Japan
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Update the Warning and Precautions section of the Product Monograph for drug reaction and Eosinophilia and systemic symptoms (DRESS)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABILIFY | Not yet assigned | — |
Medicinal ingredients
- ARIPIPRAZOLE 15 MG per MG
- ARIPIPRAZOLE 2 MG per MG
- ARIPIPRAZOLE 30 MG per MG
- ARIPIPRAZOLE 10 MG per MG
- ARIPIPRAZOLE 20 MG per MG
- ARIPIPRAZOLE 5 MG per MG